Tags

Type your tag names separated by a space and hit enter

Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mol Cancer. 2017 06 07; 16(1):101.MC

Abstract

Uterine smooth muscle tumors range from benign leiomyomas to malignant leiomyosarcomas. Based on numerous molecular studies, leiomyomas and leiomyosarcomas mostly lack shared mutations and the majority of tumors are believed to develop through distinct mechanisms. To further characterize the molecular variability among uterine smooth muscle tumors, and simultaneously insinuate their potential malignant progression, we examined the frequency of known genetic leiomyoma driver alterations (MED12 mutations, HMGA2 overexpression, biallelic FH inactivation) in 65 conventional leiomyomas, 94 histopathological leiomyoma variants (18 leiomyomas with bizarre nuclei, 22 cellular, 29 highly cellular, and 25 mitotically active leiomyomas), and 51 leiomyosarcomas. Of the 210 tumors analyzed, 107 had mutations in one of the three driver genes. No tumor had more than one mutation confirming that all alterations are mutually exclusive. MED12 mutations were the most common alterations in conventional and mitotically active leiomyomas and leiomyosarcomas, while leiomyomas with bizarre nuclei were most often FH deficient and cellular tumors showed frequent HMGA2 overexpression. Highly cellular leiomyomas displayed the least amount of alterations leaving the majority of tumors with no known driver aberration. Our results indicate that based on the molecular background, histopathological leiomyoma subtypes do not only differ from conventional leiomyomas, but also from each other. The presence of leiomyoma driver alterations in nearly one third of leiomyosarcomas suggests that some tumors arise through leiomyoma precursor lesion or that these mutations provide growth advantage also to highly aggressive cancers. It is clinically relevant to understand the molecular background of various smooth muscle tumor subtypes, as it may lead to improved diagnosis and personalized treatments in the future.

Authors+Show Affiliations

Research Programs Unit, Genome-Scale Biology Research Program and Medicum, Department of Medical and Clinical Genetics, FIN-00014 University of Helsinki, P.O. Box 63, Helsinki, Finland. netta.makinen@helsinki.fi.Research Programs Unit, Genome-Scale Biology Research Program and Medicum, Department of Medical and Clinical Genetics, FIN-00014 University of Helsinki, P.O. Box 63, Helsinki, Finland.Department of Pharmacology, Physiology and Neuroscience, USC School of Medicine, University of South Carolina, Columbia, SC, 29209, USA.Department of Pathology, Laboratory of Helsinki University Hospital (HUSLAB), Helsinki University Hospital and Medicum, FIN-00014 University of Helsinki, P.O. Box 21, Helsinki, Finland.Research Programs Unit, Genome-Scale Biology Research Program and Medicum, Department of Medical and Clinical Genetics, FIN-00014 University of Helsinki, P.O. Box 63, Helsinki, Finland. pia.vahteristo@helsinki.fi.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28592321

Citation

Mäkinen, Netta, et al. "Characterization of MED12, HMGA2, and FH Alterations Reveals Molecular Variability in Uterine Smooth Muscle Tumors." Molecular Cancer, vol. 16, no. 1, 2017, p. 101.
Mäkinen N, Kämpjärvi K, Frizzell N, et al. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Mol Cancer. 2017;16(1):101.
Mäkinen, N., Kämpjärvi, K., Frizzell, N., Bützow, R., & Vahteristo, P. (2017). Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Molecular Cancer, 16(1), 101. https://doi.org/10.1186/s12943-017-0672-1
Mäkinen N, et al. Characterization of MED12, HMGA2, and FH Alterations Reveals Molecular Variability in Uterine Smooth Muscle Tumors. Mol Cancer. 2017 06 7;16(1):101. PubMed PMID: 28592321.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. AU - Mäkinen,Netta, AU - Kämpjärvi,Kati, AU - Frizzell,Norma, AU - Bützow,Ralf, AU - Vahteristo,Pia, Y1 - 2017/06/07/ PY - 2016/08/29/received PY - 2017/06/01/accepted PY - 2017/6/9/entrez PY - 2017/6/9/pubmed PY - 2018/3/27/medline KW - FH KW - HMGA2 KW - Histopathological uterine leiomyoma variants KW - MED12 KW - Uterine leiomyoma KW - Uterine leiomyosarcoma SP - 101 EP - 101 JF - Molecular cancer JO - Mol. Cancer VL - 16 IS - 1 N2 - Uterine smooth muscle tumors range from benign leiomyomas to malignant leiomyosarcomas. Based on numerous molecular studies, leiomyomas and leiomyosarcomas mostly lack shared mutations and the majority of tumors are believed to develop through distinct mechanisms. To further characterize the molecular variability among uterine smooth muscle tumors, and simultaneously insinuate their potential malignant progression, we examined the frequency of known genetic leiomyoma driver alterations (MED12 mutations, HMGA2 overexpression, biallelic FH inactivation) in 65 conventional leiomyomas, 94 histopathological leiomyoma variants (18 leiomyomas with bizarre nuclei, 22 cellular, 29 highly cellular, and 25 mitotically active leiomyomas), and 51 leiomyosarcomas. Of the 210 tumors analyzed, 107 had mutations in one of the three driver genes. No tumor had more than one mutation confirming that all alterations are mutually exclusive. MED12 mutations were the most common alterations in conventional and mitotically active leiomyomas and leiomyosarcomas, while leiomyomas with bizarre nuclei were most often FH deficient and cellular tumors showed frequent HMGA2 overexpression. Highly cellular leiomyomas displayed the least amount of alterations leaving the majority of tumors with no known driver aberration. Our results indicate that based on the molecular background, histopathological leiomyoma subtypes do not only differ from conventional leiomyomas, but also from each other. The presence of leiomyoma driver alterations in nearly one third of leiomyosarcomas suggests that some tumors arise through leiomyoma precursor lesion or that these mutations provide growth advantage also to highly aggressive cancers. It is clinically relevant to understand the molecular background of various smooth muscle tumor subtypes, as it may lead to improved diagnosis and personalized treatments in the future. SN - 1476-4598 UR - https://www.unboundmedicine.com/medline/citation/28592321/Characterization_of_MED12_HMGA2_and_FH_alterations_reveals_molecular_variability_in_uterine_smooth_muscle_tumors_ L2 - https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-017-0672-1 DB - PRIME DP - Unbound Medicine ER -